Proyecto De Biomedicina Cima, S.l.

Digna Biotech, S.l.

Rojecto De Biomedicina Cima S.l.

Francisco Borras Cuesta

Juan José Lasarte Sagastibelza

Jesus Prieto Valtuena

Ignacio José Ezquerro Saenz

Juan Manuel Irache Garreta

Jesús Maria Prieto Valtueña

Inés Noelia Casares Lagar

Juan Jose Lasarte Sagastibelza

Pablo Sarobe Ugarriza

Javier Dotor De Las Herrerías

Ana Belen Lopez Vazquez

Javier Dotor De Las Herrerias

Fernando Martinez Galan

Jesús Prieto Valtuena

Marta Ruiz Egozcue

Ana Belén Lopez Vazquez

Aintzane Zabaleta Azpiroz

The described peptides possess the capacity to bind to Transforming Growth Factor TGF-&#x3b2;1 (TGF-&#x3b2;1), and are potential inhibitors of the biological activity of TGF-&#x3b2;1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-&#x3b2;1 expression.

Peptides with the capacity to bind to transforming growth factor &#x3b2;1 (TGF-&#x3b2;1)

A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-&#x3b2;, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-&#x3b2;, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.

Method for the treatment of skin fibrosis and suitable compositions for such treatment

Antagonistic synthetic peptides, obtained from TGF&#x3b2;1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

TGF&#x3b2;1-inhibitor peptides

TGF&#x3b2;1 inhibitor peptides

Growing community of inventors

Pamplona, Spain

Francisco Borras Cuesta